Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 797 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Aiming to Support Cancer Research, ESMO Calls on the European Council... August 28, 2026 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 Sustainability a major focus of our 17th year partnering with TK... October 11, 2021 Woman with Breast Cancer May Have Saved Her Twin’s Life by... October 16, 2020 Load more HOT NEWS Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer
